Genmab — Februar 2015
-
Jeg kan også godt lide Nordeas udlægning "Genmab og Johnson & Johnson har offentliggjort nye stærke data for cancermidlet
Daratumumab. Dataene er rigeligt stærke til, at vi forventer, at Johnson & Johnson vil indsende ansøgning om godkendelse." Jeg kan især godt lide "rigeligt stærke":-) -
deres første guidiance var 145 for 2015
-
de endte på 103
in Q4 2014 totaled GBP 12.3 million
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind